Jazz Pharmaceuticals plc financial data

Symbol
JAZZ on Nasdaq
Location
Dublin
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 24 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 197% % -37%
Quick Ratio 24% % -41%
Return On Assets -3.1% % -166%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61,560,350 shares -0.12%
Common Stock, Shares, Outstanding 61,435,000 shares 1.3%
Entity Public Float $6,250,820,994 USD -2.5%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 60,981,000 shares -1.4%
Weighted Average Number of Shares Outstanding, Diluted 60,981,000 shares -7.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $4,267,586,000 USD 4.9%
Costs and Expenses $4,697,826,000 USD 40%
Operating Income (Loss) $430,240,000 USD -160%
Income Tax Expense (Benefit) $272,443,000 USD -198%
Net Income (Loss) Attributable to Parent $356,148,000 USD -164%
Earnings Per Share, Basic -5.84 USD/shares -164%
Earnings Per Share, Diluted -5.84 USD/shares -168%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,391,899,000 USD -42%
Accounts Receivable, after Allowance for Credit Loss, Current $830,747,000 USD 16%
Inventory, Net $416,962,000 USD -13%
Other Assets, Current $323,954,000 USD 24%
Assets, Current $4,166,043,000 USD -10%
Deferred Income Tax Assets, Net $869,130,000 USD 55%
Operating Lease, Right-of-Use Asset $58,880,000 USD 9.9%
Intangible Assets, Net (Excluding Goodwill) $4,429,510,000 USD -6.9%
Goodwill $1,829,340,000 USD 6.6%
Other Assets, Noncurrent $99,030,000 USD -13%
Assets $11,659,340,000 USD -2.9%
Accounts Payable, Current $122,061,000 USD 57%
Accrued Liabilities, Current $1,034,170,000 USD 14%
Liabilities, Current $2,242,521,000 USD 116%
Deferred Income Tax Liabilities, Net $594,470,000 USD -12%
Operating Lease, Liability, Noncurrent $50,892,000 USD 31%
Other Liabilities, Noncurrent $124,519,000 USD 44%
Accumulated Other Comprehensive Income (Loss), Net of Tax $568,598,000 USD 40%
Retained Earnings (Accumulated Deficit) $646,176,000 USD -43%
Stockholders' Equity Attributable to Parent $4,318,584,000 USD 5.5%
Liabilities and Equity $11,659,340,000 USD -2.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $429,784,000 USD 61%
Net Cash Provided by (Used in) Financing Activities $813,466,000 USD -1338%
Net Cash Provided by (Used in) Investing Activities $168,931,000 USD 38%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 61,435,000 shares 1.3%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $550,918,000 USD -776%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,391,899,000 USD -42%
Deferred Tax Assets, Valuation Allowance $529,674,000 USD 4%
Deferred Tax Assets, Gross $1,869,723,000 USD 18%
Operating Lease, Liability $65,170,000 USD 22%
Depreciation $10,425,000 USD 36%
Payments to Acquire Property, Plant, and Equipment $13,881,000 USD 101%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $22,921,000 USD -95%
Lessee, Operating Lease, Liability, to be Paid $79,223,000 USD 26%
Operating Lease, Liability, Current $14,278,000 USD -0.37%
Lessee, Operating Lease, Liability, to be Paid, Year Two $15,851,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year One $18,031,000 USD 8.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.069 pure 4.5%
Deferred Income Tax Expense (Benefit) $43,833,000 USD 34%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14,053,000 USD 46%
Lessee, Operating Lease, Liability, to be Paid, Year Three $13,375,000 USD 30%
Deferred Tax Assets, Operating Loss Carryforwards $394,614,000 USD 28%
Unrecognized Tax Benefits $143,022,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Four $8,684,000 USD -3.7%
Amortization of Intangible Assets $654,661,000 USD 4.4%
Deferred Tax Assets, Net of Valuation Allowance $1,340,049,000 USD 25%
Share-based Payment Arrangement, Expense $291,133,000 USD 17%